Stellar Biotechnologies, Inc., a biotechnology company, engages in the aquaculture, research and development, manufacture, and commercialization of keyhole limpet hemocyanin (KLH) protein primarily in Europe, the United States, and Asia. It provides KLH, an immune-stimulating molecule used as an active pharmaceutical ingredient in various immunotherapies; and as an injectable product to assess immune response. The company offers its KLH protein under the Stellar KLH brand. Its products include Stellar KLH protein in various grades, formulations, and configurations for preclinical and clinical applications, as well as certain KLH-based in vitro diagnostic kits for preclinical use. The company...
332 East Scott Street
Port Hueneme, CA 93041
Stellar Biotechnologies, Inc. Reports Unaudited Consolidated Earnings Results for the Second Quarter and Six Months Ended March 31, 2017
May 9 17
Stellar Biotechnologies, Inc. reported unaudited consolidated earnings results for the second quarter and six months ended March 31, 2017. For the quarter, the company reported total revenues of $63,019 compared to $326,335 for the same period a year ago. The change in Revenue was due to a decrease in product sales volume. Loss from operations was $1,147,557 compared to $1,095,943 for the same period a year ago. Net loss was $1,103,677 or $0.11 per basic and diluted share compared to $861,010 or $0.10 per basic and diluted share for the same period a year ago.
For the six months, the company reported total revenues of $204,875 compared to $814,495 for the same period a year ago. Loss from operations was $2,562,033 compared to $2,403,297 for the same period a year ago. Net loss was $2,589,349 or $0.26 per basic and diluted share compared to $2,490,813 or $0.30 per basic and diluted share for the same period a year ago. Net cash used in operating activities was $2,641,197 compared to $2,247,526 for the same period a year ago. Acquisition of property, plant and equipment was $126,876 compared to $263,242 for the same period a year ago.
Stellar Biotechnologies, Inc. and Matrivax Inc. Enters into Agreement for Technology Transfer and Purchase Agreement Related to Stellar's Proprietary Clostridium Difficile Technology
Mar 13 17
Stellar Biotechnologies, Inc. and Matrivax Inc. announced that the companies have entered into a technology transfer and purchase agreement related to Stellar's proprietary Clostridium difficile technology. Under the terms of the agreement, Stellar will transfer its proprietary rights and know-how of immunogens and vaccine technology for a life-threatening pathogenic bacteria known as Clostridium difficile. Stellar advanced this technology through exploratory preclinical studies completed under an exclusive license of the patented immunotherapy technology from the University of Guelph, Canada.
Stellar Biotechnologies Inks Multiyear KLH Supply Agreement with Amaran Biotechnology
Mar 4 17
Stellar Biotechnologies and Amaran Biotechnology have entered into an exclusive agreement where Stellar will supply KLH to Amaran Biotechnology.